唑来膦酸对原发性骨质疏松症患者骨密度、骨代谢及脆性骨折发生率的影响

Effects of Zoledronic Acid on Bone Mineral Density,Bone Metabolism and Incidence of Fragility Fractures in Patients with Primary Osteoporosis

目的观察原发性骨质疏松症患者采取唑来膦酸治疗的效果及对其脆性骨折、骨代谢、骨密度的影响。方法选取我院2017年12月至2018年12月收治的原发性骨质疏松症患者66例,根据入院的先后顺序分组,分为观察组和对照组,每组33例,对照组采取碳酸钙D_3治疗,观察组给予唑来膦酸治疗,对比两组骨密度(BMD)、骨痛评分、骨代谢指标、治疗总有效率、脆性骨折率。结果观察组骨痛评分、治疗总有效率、脆性骨折发生率、BALP、β-CTX、DPD/Cr值、TRACP-5b血清hCT均优于对照组,对比差异有统计学意义(P <0.05)。结论对原发性骨质疏松症患者采取唑来膦酸治疗效果良好,值得推广。

Objective To observe the effect of zoledronic acid on fragile fracture,bone metabolism and bone mineral density in patients with primary osteoporosis.Methods Sixty-six patients with primary osteoporosis admitted to our hospital from December 2017 to December 2018 were divided into observation group and control group according to the order of admission,with 33 cases in each group.The control group was treated with calcium carbonate D3,while the observation group was treated with zoledronic acid.The BMD,bone pain score,bone metabolism index,total effective rate and fragile fracture rate of the two groups were compared.Results The score of bone pain,total eff ective rate,incidence of fragility fracture,BALP,β-CTX,DPD/CR,TRACP-5b and serum hCT in the observation group were better than those in the control group,and the diff erence was statistically signifi cant(P<0.05).Conclusion Zoledronic acid is eff ective in the treatment of primary osteoporosis,which is worth popularizing.